Trial
NCT01834274
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
Fasiglifam (TAK-875)
Why stopped
Due to potential concerns about liver safety (See Detailed Description)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-28